Histone deacetylases as targets for treatment of multiple diseases
about
Role of histone deacetylases in pancreas: Implications for pathogenesis and therapyHistone Deacetylases and Cardiometabolic DiseasesTranscriptional regulation by Pho23 modulates the frequency of autophagosome formationPhase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Minireview: The versatile roles of lysine deacetylases in steroid receptor signalingA potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses.Quantitative analysis of injury-induced anterior subcapsular cataract in the mouse: a model of lens epithelial cells proliferation and epithelial-mesenchymal transitionProportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patientsKDAC8 with High Basal Velocity Is Not Activated by N-Acetylthioureas.Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathwayRole of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.Emerin and histone deacetylase 3 (HDAC3) cooperatively regulate expression and nuclear positions of MyoD, Myf5, and Pax7 genes during myogenesis.Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetesEffect of Fusarium-Derived Metabolites on the Barrier Integrity of Differentiated Intestinal Porcine Epithelial Cells (IPEC-J2).The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells.A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells.Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.Epigenetic approaches for bipolar disorder drug discovery.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Purification of metal-dependent lysine deacetylases with consistently high activity.Lysine Deacetylases Exhibit Distinct Changes in Activity Profiles Due to Fluorophore Conjugation of Substrates.Histone Deacetylase Inhibitors as Anticancer Drugs.A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.An update on the epigenetics of glioblastomas.A Novel View of the Adult Stem Cell Compartment From the Perspective of a Quiescent Population of Very Small Embryonic-Like Stem Cells.Trichostatin A Inhibits Retinal Pigmented Epithelium Activation in an In Vitro Model of Proliferative Vitreoretinopathy.KDAC8 substrate specificity quantified by a biologically relevant, label-free deacetylation assay.Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy.The Novel HDAC8 Inhibitor WK2-16 Attenuates Lipopolysaccharide-Activated Matrix Metalloproteinase-9 Expression in Human Monocytic Cells and Improves Hypercytokinemia In Vivo.Long non-coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non-small cell lung cancer.Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.Resveratrol suppresses inflammatory responses in endometrial stromal cells derived from endometriosis: a possible role of the sirtuin 1 pathway.Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells.Chelatable trace zinc causes low, irreproducible KDAC8 activity.
P2860
Q26774080-05C6C17A-F8FC-491B-BACF-83DB9EB2FF3CQ26800062-FEA73DCB-7759-45BD-AAD4-42A8A5019CC4Q28655640-97EB8884-CEEC-4EC3-984C-7C7FDBEFD498Q33437309-3042447B-011A-4838-AAC4-431207994F98Q33632070-E91FA261-32DE-4076-91F6-B00F529A6679Q33960767-623EA796-49D7-46B1-A423-4D8AA5597FF3Q34647217-3191ACA9-199B-40C6-AF53-D8A7B7758125Q35558466-F7065B8C-03A8-4005-9DA8-34CCB00C2E01Q35692323-F4892F40-C54D-4058-8183-C32768C53AD9Q35888924-4259B900-539B-424D-A757-04652F9DC14EQ35904204-00AA5636-7FB1-4455-B34B-5F7E82069990Q36000612-781AC0B2-8214-40E9-818E-4F42EC6EAEECQ36047009-B2D577E2-F1A6-492D-8277-0A9CD5366247Q36791375-1C9CDFCA-FBCE-47B0-B681-0FDBC1469960Q37126439-6375D40E-1DDD-45FC-AC5A-0E4FA08813F6Q37178611-43A3979D-EE3E-4D30-A58B-D928ADC7E5FFQ37436828-B15C24BB-EB49-438E-9393-397A7B996C5DQ37450471-9861BA02-03A6-49EE-ACED-7E74FD0A454DQ37577442-909F03AF-B5DA-4961-B69F-42D98BA41216Q37708375-4F425D0B-B95E-4A3A-B0CF-D5A9D83AA477Q37724028-90444775-46C4-4320-8027-7D4D255FDB13Q38204487-7FB17848-5FFD-4E05-B322-19A73266AD37Q38215889-C233A981-4E4E-4EBE-8FB8-E364FBFAB6D9Q38233723-65EE88A7-35AF-4492-AE58-988EE23D4DD5Q38398820-BEED8BE1-5F77-47E1-829B-E6561056C74CQ38658061-22DE4402-970B-4234-B379-DF39C8364432Q38696932-8B166AF1-9F89-414B-8CB1-E6C25D3534B4Q38818334-9393740F-C037-49B9-AA0C-D6856784282BQ38944047-9DF0B3C2-5239-4929-B5DF-75FE642957E0Q39069176-B0939515-5266-4248-8ED9-CD4BF704C74BQ39520301-C8815EE3-B8F1-4F84-9064-6D9AA79AC487Q39719386-FE8A8E0A-D7E6-4F26-80C1-5698E3CD317AQ41029112-237ECC25-F75F-45CB-ACF5-BD6239ADAC57Q41181662-10FA951E-600B-4676-AD99-82F964771367Q41520508-CAAFB807-39D4-44D4-9EA6-A6396D32A683Q42012248-6AD881C5-CCB1-4B4E-A955-FEDD4F96746EQ45621034-090C7815-937F-4881-A608-32F3DDE59DF2Q46349820-A3998CCD-761D-48D9-9663-282F430E72D9Q47141836-BFE53D6E-7EF1-42AF-A903-7D70262B7E57Q47443903-CF75558C-5FBE-418B-8106-C9EC5BBCFE0F
P2860
Histone deacetylases as targets for treatment of multiple diseases
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Histone deacetylases as targets for treatment of multiple diseases
@ast
Histone deacetylases as targets for treatment of multiple diseases
@en
Histone deacetylases as targets for treatment of multiple diseases
@nl
type
label
Histone deacetylases as targets for treatment of multiple diseases
@ast
Histone deacetylases as targets for treatment of multiple diseases
@en
Histone deacetylases as targets for treatment of multiple diseases
@nl
prefLabel
Histone deacetylases as targets for treatment of multiple diseases
@ast
Histone deacetylases as targets for treatment of multiple diseases
@en
Histone deacetylases as targets for treatment of multiple diseases
@nl
P2093
P2860
P3181
P356
P1433
P1476
Histone deacetylases as targets for treatment of multiple diseases
@en
P2093
Haidong Yan
Jinhua Tang
Shougang Zhuang
P2860
P304
P3181
P356
10.1042/CS20120504
P407
P577
2013-06-01T00:00:00Z